Person:
SÜMBÜL ŞEKERCİ, BETÜL

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
BETÜL
Last Name
SÜMBÜL ŞEKERCİ
Name
Email Address
Birth Date

Filters

2022 - 20236
Reset filters

Settings

Author: ŞEKERCİ, ABDÜSSELAM ×

Search Results

Now showing 1 - 6 of 6
  • No Thumbnail Available
    PublicationMetadata only
    Association between the peripheral blood parameters and Alzheimer’s disease in patients with type-2 diabetes mellitus: a case–control study
    (2022-10-01T00:00:00Z) Sümbül Şekerci, Betül; Şekerci, Abdüsselam; Gelişin, Özlem; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM
  • No Thumbnail Available
    PublicationMetadata only
    Low Serum 25-Hydroxyvitamin D Concentration And Alzheimer-s Disease Risk in Patients with Type-2 Diabetes Mellitus
    (2022-05-26T00:00:00Z) Sümbül Şekerci, Betül; Gelişin, Özlem; Şekerci, Abdüsselam; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM
  • No Thumbnail Available
    PublicationMetadata only
    Diyabet ve Prediyabet Hastalarındaki Kognitif Bozulmanın Hipertrigliseridemi İle İlişkisi
    (2023-06-14) Şekerci A.; Sümbül Şekerci B.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    FARMASÖTİK BAKIM HİZMETİNİN DİYABET PROGNOZUNA ETKİLERİNİN DEĞERLENDİRİLMESİ
    (2022-05-07T00:00:00Z) Kutluay, Nur Bucu; Bektay, Muhammed Yunus; Sümbül Şekerci, Betül; Şekerci, Abdüsselam; İzzettin, Fikret Vehbi; BEKTAY, MUHAMMED YUNUS; SÜMBÜL ŞEKERCİ, BETÜL; ŞEKERCİ, ABDÜSSELAM; İZZETTİN, FIKRET VEHBI
  • No Thumbnail Available
    PublicationMetadata only
    Diyabet Hastalarında Gözardı Edilen Bir Komplikasyon: Kognitif Bozulma.
    (2022-12-23) Şekerci A.; Sümbül Şekerci B.; Selvitop R.; Yüksel Salduz Z. İ.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL; YÜKSEL SALDUZ, ZEYNEB İREM
  • No Thumbnail Available
    PublicationMetadata only
    Cognition And Anticholinergic Burden In Type 2 Diabetes Mellitus
    (2022-12-03) Şekerci A.; Sümbül Şekerci B.; Selvitop R.; Yüksel Salduz Z. İ.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL; YÜKSEL SALDUZ, ZEYNEB İREM
    Background and Objective: Cognitive impairment is one of the most important complications of type 2 diabetes mellitus (T2DM). Anticholinergic burden can cause cognitive decline. The aim of this study is to investigate the relationship between cognitive impairment and anticholinergic burden in patients with T2DM. Method: Seventy-three patients diagnosed with T2DM according to ADA criteria and using oral antidiabetic drugs for treatment participated in our study. Patients with a history of serious psychiatric (e.g.,major depressive disorder) or neurological disease (e.g., cerebrovascular disease, brain tumor, head trauma) were excluded. Main outcome measures: The cognition of the patients was evaluated with the Montreal Cognitive Assessment (MoCA). The cut-off score of the MoCA for cognitive impairment is 21 according to the validation of the Turkish Version. The drugs used by the patients were analyzed and the anticholinergic burden was calculated according to the anticholinergic cognitive burden (ACB) scale. Results: The mean age of the patients in our study was 50.60 (± 8.19). While ACB was not observed in the drugs of 67 patients, 5 patients used drugs with ACB Score of 1. The cognition of 45 (61.6%) patients with T2DM was impaired and 28 (38.3%) patients were normal. There is no significant difference in age of cognition groups. Attention (p \0.001), language (p \0.001) and orientation (p\ 0.001) scores were significantly worse in T2DM with impaired cognition. No significant difference was found between the ACB burden of DM patients with normal cognition and impaired cognition. Conclusion: In our study, no relationship was found between cognitive impairment in T2DM and ACB. Future studies involving larger sample and higher ACB may provide more detailed information.